beta

AERI

Aerie Pharmaceuticals, Inc.

Aeri

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.

Market Cap: 975 Million

Primary Exchange: NASDAQ

Website: http://www.aeriepharma.com

Shares Outstanding: 46.3 Million

Float: 37.8 Million

Dividend: (%)

Beta: 1.11697499912294

Sector: Health Technology

Industry: Pharmaceuticals: Other

Ethical Flags

Animal testing

Longest drawdown: 486 trading days

From: 2018-07-19 To: 2019-12-09

Lowest Point:

Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences

via: Business Wire at 2019-06-11 03:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that … read more...

Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences

via: Business Wire at 2019-06-11 03:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that … read more...

Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences

via: Business Wire at 2019-06-11 03:30:00:000

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud